Rubius Therapeutics
OverviewSuggest Edit
Rubius Therapeutics is developing Red-Cell Therapeutics™ (RCTs™) as a new class of medicines to address a wide array of indications, with leading applications in cancer, rare and autoimmune disease, as well as additional potential in hemophilia, infectious and metabolic diseases.
| Type | Public | |
| Founded | 2013 | |
| HQ | Cambridge, US | Map |
| Website | rubiustx.com |
Recent NewsAll News
- Rubius Therapeutics Reports Second Quarter 2020 Financial Results and Positive Progress Across Pipeline
- Rubius Therapeutics Reports Fourth Quarter and Full-Year 2019 Financial Results and Announces Strategic Focus on Oncology and Autoimmunity
- Rubius Therapeutics Reports Third Quarter 2019 Financial Results and Operational Progress
- Rubius Therapeutics Reports Second Quarter 2019 Financial Results and Operational Progress
Key People/Management at Rubius Therapeutics
Pablo J. Cagnoni
Chief Executive Officer, Director
Christina Coughlin
Chief Medical Officer
Andrew Oh
Chief Financial Officer
Kris Elverum
Senior Vice President, Business Development and Strategy
Tom Wickham
Senior Vice President, Discovery
Spencer Fisk
Senior Vice President & Chief Technical Operations Officer
Rubius Therapeutics Office Locations
Rubius Therapeutics has offices in Cambridge and Smithfield
Cambridge, US (HQ)
399 Binney St #300
Smithfield, US
100 Technology Way
Rubius Therapeutics Financials and Metrics
Rubius Therapeutics Revenue
| USD | |
|---|---|
Net income (Q2, 2020) | (37.9m) |
EBIT (Q2, 2020) | (37.7m) |
Market capitalization (18-Sept-2020) | 445.0m |
Closing stock price (18-Sept-2020) | 5.5 |
Cash (30-Jun-2020) | 129.2m |
EV | 434.8m |
Rubius Therapeutics's current market capitalization is $445 m.
Annual
Quarterly
| USD | Q1, 2017 | Q1, 2018 | Q2, 2018 | Q3, 2018 | Q1, 2019 | Q2, 2019 | Q3, 2019 | Q1, 2020 | Q2, 2020 |
|---|---|---|---|---|---|---|---|---|---|
General and administrative expense | 1.1m | 5.8m | 16.3m | 13.2m | 13.5m | 13.8m | 15.0m | 12.7m | 11.6m |
R&D expense | 3.7m | 9.7m | 12.0m | 14.4m | 20.9m | 27.5m | 33.5m | 36.2m | 26.1m |
Operating expense total | 4.8m | 15.4m | 28.2m | 27.6m | 34.4m | 41.3m | 48.5m | 48.9m | 37.7m |
EBIT | (4.8m) | (15.4m) | (28.2m) | (27.6m) | (34.4m) | (41.3m) | (48.5m) | (48.8m) | (37.7m) |
Annual
Annual
Quarterly
| USD | Q1, 2017 | Q1, 2018 | Q2, 2018 | Q3, 2018 | Q1, 2019 | Q2, 2019 | Q3, 2019 | Q1, 2020 | Q2, 2020 |
|---|---|---|---|---|---|---|---|---|---|
Net Income | (4.9m) | (15.3m) | (44.4m) | (62.0m) | (32.6m) | (72.0m) | (119.0m) | ||
Depreciation and Amortization | 48.0k | 227.0k | 502.0k | 879.0k | 661.0k | 1.4m | 2.3m | 1.8m | 3.6m |
Accounts Payable | 937.0k | 452.0k | 3.0m | 2.4m | (966.0k) | (4.7m) | 3.2m | 905.0k | 3.1m |
Cash From Operating Activities | (3.1m) | (10.9m) | (20.8m) | (38.6m) | (22.9m) | (52.7m) | (81.5m) | (40.0m) | (68.6m) |
| USD | FY, 2016 |
|---|---|
Debt/Equity | 6.3 x |
Debt/Assets | 1.5 x |
Financial Leverage | 4.1 x |
Rubius Therapeutics Cybersecurity Score
Rubius Therapeutics Online and Social Media Presence
940 Twitter followers
Rubius Therapeutics has 940 Twitter Followers. The number of followers has increased 2.8% month over month and increased 8.3% quarter over quarter
Rubius Therapeutics's Trends
Twitter Engagement Stats for @rubius_tx
227
Tweets
243
Following
940
Followers
6
Tweets last 30 days
3.8
Avg. likes per Tweet
100%
Tweets with engagement
Rubius Therapeutics News and Updates
August 10, 2020
Rubius Therapeutics Reports Second Quarter 2020 Financial Results and Positive Progress Across Pipeline
Strong Momentum in Dosing Patients and Manufacturing Clinical Supply for RTX-240 Phase 1/2 Solid Tumor Clinical Trial
March 12, 2020
Rubius Therapeutics Reports Fourth Quarter and Full-Year 2019 Financial Results and Announces Strategic Focus on Oncology and Autoimmunity
RTX-240 Investigational New Drug Application for Solid Tumors Cleared by U.S. FDA
November 14, 2019
Rubius Therapeutics Reports Third Quarter 2019 Financial Results and Operational Progress
CAMBRIDGE, Mass., Nov. 14, 2019 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines, today reported third quarter 2019 financial results and pro…
August 13, 2019
Rubius Therapeutics Reports Second Quarter 2019 Financial Results and Operational Progress
On Track to Report Initial Clinical Data from Phase 1b Clinical Trial of RTX-134 for Phenylketonuria by Year-End
May 15, 2019
Rubius Therapeutics Reports First Quarter 2019 Financial Results and Operational Progress
Enrollment for Phase 1b Trial of RTX-134 for Phenylketonuria on Track for Second Quarter 2019; Initial Clinical Data Anticipated in Second Half 2019
February 27, 2019
Rubius Therapeutics Announces Poster Presentations at the 2019 American Association for Cancer Research Annual Meeting
CAMBRIDGE, Mass., Feb. 27, 2019 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a biopharmaceutical company that is generating red blood cells and bioengineering them into an entirely new class of cellular medicines, today announced that the company will present preclinical data from …
Rubius Therapeutics Blogs
May 12, 2020
Rubius Therapeutics Highlights Preclinical Data for RTX-321, a Red Cell Therapeutic™ Oncology Product Candidate for HPV-Positive Cancers, at the American Society of Gene & Cell Therapy 23rd Annual Meeting
Rubius Therapeutics Highlights Preclinical Data for RTX-321, a Red Cell Therapeutic™ Oncology Product Candidate for HPV-Positive Cancers, at the American Society of Gene & Cell Therapy 23rd Annual Meeting
Content Import
Tue, 05/12/2020 - 06:01
Rubius Therapeutics Highlights Preclinical…
May 12, 2020
An Engineered Allogeneic Artificial Antigen-Presenting Red Cell Therapeutic, RTX-321, for HPV16+ Associated Cancers Promotes Antigen-Specific T Cell Activation and Expansion
Shamael R. Dastagir, Xuqing Zhang, Albert Lee, Timothy J. Lyford, Jennifer M. Mellen, Andrea Schmidt, Mary Gribble, Chris Moore, Thomas J. Wickham, and Tiffany F. Chen RTX-321 Audio Introduction Your browser does not support the audio element.
The post An Engineered Allogeneic Artificial Antigen-Pre…
May 12, 2020
Engineered Red Cell Therapeutics as Artificial Antigen Presenting Cells Promote in vitro Expansion of both Naïve and Exhausted CD4+ T Cells
Engineered Red Cell Therapeutics as Artificial Antigen Presenting Cells Promote in vitro Expansion of both Naïve and Exhausted CD4+ T Cells RCT MHC II aAPC Audio Introduction Your browser does not support the audio element.
The post Engineered Red Cell Therapeutics as Artificial Antigen Presenting C…
May 11, 2020
Rubius Therapeutics Reports First Quarter 2020 Financial Results and Provides Operational Update
Completed Strategic Reprioritization of Pipeline to Focus on Oncology and Autoimmunity Dosed First Patient in Phase 1/2 Clinical Trial of RTX-240 for Advanced Solid Tumors Successfully Produced cGMP Clinical Supply of RTX-240 from Fully Owned Manufacturing Facility Strong Cash Position CAMBRIDGE,
May 07, 2020
Rubius Therapeutics Announces Dosing of First Patient in Phase 1/2 Trial of RTX-240, an Allogeneic Cellular Therapy, for the Treatment of Solid Tumors
CAMBRIDGE, Mass. , May 07, 2020 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines, today announced that the first patient has been dosed in
May 04, 2020
Rubius Therapeutics to Announce First Quarter 2020 Financial Results
CAMBRIDGE, Mass. , May 04, 2020 (GLOBE NEWSWIRE) -- Rubius Therapeutics , Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines, today announced plans to report first quarter 2020
Rubius Therapeutics Frequently Asked Questions
When was Rubius Therapeutics founded?
Rubius Therapeutics was founded in 2013.
Who are Rubius Therapeutics key executives?
Rubius Therapeutics's key executives are Pablo J. Cagnoni, Christina Coughlin and Andrew Oh.
How many employees does Rubius Therapeutics have?
Rubius Therapeutics has 174 employees.
Who are Rubius Therapeutics competitors?
Competitors of Rubius Therapeutics include ImCheck Therapeutics, Centivax and MyoTherix.
Where is Rubius Therapeutics headquarters?
Rubius Therapeutics headquarters is located at 399 Binney St #300, Cambridge.
Where are Rubius Therapeutics offices?
Rubius Therapeutics has offices in Cambridge and Smithfield.
How many offices does Rubius Therapeutics have?
Rubius Therapeutics has 2 offices.
Learn about Craft real-time company insights
Receive alerts for 300+ data fields across thousands of companies